Related Experiment Video
Updated: Nov 17, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Smad7 suppresses melanoma lung metastasis by impairing Tregs migration to the tumor microenvironment
Deliang Ma1, Li Qiao1, Bingnan Guo2,3
1Department of Oncology, Linyi Central Hospital Linyi 276400, Shandong, China.
Abstract:
Transforming growth factor β (TGF-β) signaling plays critical roles in both physiological and pathological conditions. In the tumor microenvironment, TGF-β are well demonstrated as a tumor inducer, which also promote tumor growth and metastasis. SMAD family is an important TGF-β signalling transducer, which consists of receptor-regulated SMADs (R-SMADs), common-mediator SMADs (co-SMADs), and inhibitory SMADs (I-SMADs). Smad7 is one of the I-SMADs which has been proved to block TGF-β signalling transduction in both tumor cells and immune cells. Accumulated evidence has suggested SMAD7 acted as a tumor suppressor in various cancer types, such as colorectal cancer, pancreatic cancer and skin melanoma, etc. However, the role of SMAD7 in melanoma lung metastasis has not been well studied. Here, we first investigated the role of SMAD7 on tumor cell viability by overexpressing SMAD7 in murine melanoma cell line B16-F10. Our results showed that SMAD7 overexpression slightly impaired B16-F10 cells growth, promoted cell apoptosis and arrested the cell cycle at S phase. In vivo study showed that SMAD7 overexpression inhibited B16-F10 lung metastasis. Further mechanism study suggested that SMAD7 promoted T cells activation by decreasing regulatory T cells (Tregs) infiltrating into the tumor microenvironment. In summary, our results proved that tumor cell derived SMAD7 inhibited melanoma lung metastasis by impairing the migration capacity of Tregs.
Insights
Smad7, an inhibitor of transforming growth factor β (TGF-β) signaling, suppresses melanoma lung metastasis by impairing regulatory T cells (Tregs) migration. This study highlights SMAD7
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Transforming growth factor β (TGF-β) signaling is crucial in physiological and pathological processes, including cancer.
- SMAD7, an inhibitory SMAD, blocks TGF-β signaling and has shown tumor-suppressive roles in various cancers.
- The specific role of SMAD7 in melanoma lung metastasis remains understudied.
Purpose of the Study:
- To investigate the role of SMAD7 in melanoma cell viability and lung metastasis.
- To explore the underlying mechanisms by which SMAD7 influences the tumor microenvironment.
Main Methods:
- Overexpression of SMAD7 in the murine melanoma cell line B16-F10.
- Assessment of cell viability, apoptosis, and cell cycle progression.
- In vivo studies to evaluate lung metastasis.
- Analysis of T cell activation and regulatory T cells (Tregs) infiltration in the tumor microenvironment.
Main Results:
- SMAD7 overexpression slightly reduced B16-F10 cell growth, increased apoptosis, and caused S-phase cell cycle arrest.
- In vivo experiments demonstrated that SMAD7 overexpression inhibited lung metastasis of B16-F10 cells.
- SMAD7 promoted T cell activation by reducing the infiltration of Tregs into the tumor microenvironment.
Conclusions:
- Tumor cell-derived SMAD7 acts as a suppressor of melanoma lung metastasis.
- SMAD7 inhibits metastasis by impairing the migratory capacity of regulatory T cells (Tregs).
- Targeting SMAD7 could be a potential therapeutic strategy for melanoma lung metastasis.
Related Concept Videos
MicroRNAs
MicroRNAs

